Vosoritide for Injection 0.4 mg, 0.56 mg, 1.2 mg Suppliers & Bulk Manufacturers

Available Forms: Lyophilised powder vial (subcutaneous)

Available Strengths: 0.4 mg, 0.56 mg, 1.2 mg

Pack Sizes: Carton of 10 single-dose vials with diluent

Reference Brands: Voxzogo (BioMarin)

Category: Orphan Drugs

Vosoritide (Voxzogo, BioMarin) is a once-daily injection that helps children with achondroplasia grow, used while their growth plates are still open. It is supplied as 0.4 mg, 0.56 mg and 1.2 mg vials, with the dose set by body weight. PharmaTradz handles enquiries for authorised supply of the originator product (named-patient and import-permit orders), and connects developers and licensees preparing for patent and exclusivity expiry.

Product Description:

Vosoritide is a modified form of C-type natriuretic peptide (CNP). In achondroplasia, a change in the FGFR3 gene keeps the growth plates in the long bones permanently "switched down". Vosoritide works against that signal, so the growth plates can lay down new bone and the child grows faster than they otherwise would.

It is approved in the US, the EU and many other markets as Voxzogo for children with achondroplasia whose growth plates are still open. Parents or carers give it once a day as a small injection under the skin. The vial strength (0.4 mg, 0.56 mg or 1.2 mg) is chosen from the child's weight, so a hospital order normally lists the strength and the number of vials needed for a set period, for example 180 vials for six months.

Sourcing notes. Vosoritide is patented and there is no generic. Most requests we see come from countries where it is not yet registered, through named-patient or special-import routes. Treatment runs for years, so buyers should plan for continuous supply, not a single shipment. Vials are stored refrigerated, which means cold-chain shipping and temperature records are needed. The long-acting CNP product navepegritide is also listed on PharmaTradz.